Other Clinical Trial - Low Dose Radiotherapy in COVID-19 Pneumonia

Status Active, not recruiting

Clinical Trial Summary

Moderate to severe cases of SARS-associated ARDS based on inclusion/ exclusion criteria and the decision made in multi- disciplinary team are treated with 0.5 Gy whole lung radiation.

Clinical Trial Description

SARS-associated ARDS (acute respiratory distress syndrome) is the most fatal outcome of COVID-19 systemic infection. To overcome the uncontrolled inflammation leading to ARDS and respiratory failure, several drugs have been investigated in this situation with the most promising results coming from anti-inflammatory agents that directly or indirectly inhibit IL-6 and its counterparts of inflammation. Low dose radiation, as opposed to high dose, has documented anti-inflammatory effects that are exercised through various mechanisms including decrease in pro-inflammatory cytokines such as IL-6. In this pilot clinical trial, the patients are carefully selected according to inclusion /exclusion criteria and the clinical judgement of the multi- disciplinary team.Their diagnostic CT scan will be used to plan an AP/ PA radiotherapy treatment to both lungs and the set-up positioning information is obtained from anatomical landmarks. The patient will be referred for a fraction of 0.5 Gy to both lungs and for the next 28 days the clinical para-clinical and radiologic variables of disease severity will be monitored closely. Should the patient's clinical course indicate and the multi- disciplinary team approves, they may be subjected to another fraction of 0.5 Gy to a maximum of 1 Gy in two fractions at least 72 hours apart. All the patients will also receive the standard national protocol of COVID-19 management. A total of 5 patients will be enrolled in the RT arm, providing favourable results seen in the first set of patients, the team will decide on recruiting a larger number for a phase II clinical trial. ;

Study Design

Related Conditions & MeSH terms

Coronavirus Infections
COVID
SARS (Severe Acute Respiratory Syndrome)
Severe Acute Respiratory Syndrome

Clinical Trial Details

NCT number	NCT04390412
Study type	Interventional
Source	Shahid Beheshti University of Medical Sciences
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	May 4, 2020
Completion date	December 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04558125` - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism	Phase 4
Recruiting	`NCT04410510` - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19	Phase 2/Phase 3
Active, not recruiting	`NCT04420676` - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection	N/A
Completed	`NCT04419025` - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease	Phase 2
Completed	`NCT04425317` - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients	N/A
Completed	`NCT04395911` - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections	N/A
Completed	`NCT04526769` - Detecting SARS-CoV-2 in Tears
Withdrawn	`NCT04456426` - Characteristics of Patients With COVID-19 in Meta State, Colombia
Suspended	`NCT04385771` - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	N/A
Completed	`NCT04425720` - Use of Remote Monitoring for COVID-19 Patient	N/A
Completed	`NCT04419610` - RAS and Coagulopathy in COVID19	Early Phase 1
Completed	`NCT04546581` - Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)	Phase 3
Terminated	`NCT04530448` - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization	Phase 4
Completed	`NCT04435327` - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Not yet recruiting	`NCT04524156` - COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2	N/A
Completed	`NCT04441710` - Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
Completed	`NCT04357834` - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting	`NCT04392427` - New Antiviral Drugs for Treatment of COVID-19	Phase 3
Terminated	`NCT04614025` - Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19	Phase 2
Completed	`NCT04402957` - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)	Phase 2